logo

The use of active surveillance (AS) is rapidly expanding worldwide, with rates as high as 74% among patients with low-risk prostate cancer in the nationwide registry of Sweden [1].[...]
Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance Mufaddal M. Mamawala, Karthik Rao, Patricia Landis, Jonathan I. [...]
Every Week the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full arti[...]
In January 2016, in his final State of the Union address, US President Barack Obama tasked Vice President Joseph Biden with heading up a new national mission, the Cancer Moonshot, [...]
Qualitative study on decision-making by prostate cancer physicians during active surveillance Stacy Loeb*,†,‡,§, Caitlin Curnyn†, Angela Fagerlin¶,**, Ronald Scott Braithwaite† Mar[...]
The much awaited results of the STAMPEDE study of abiraterone for hormone naive prostate cancer was simultataneously presented at #ASCO17 and published ‘on line ahead of prin[...]
This patient is undergoing radiotherapy for recurrent prostate cancer. Images from Fodor et al, BJUI 2017.[...]
It should surprise no one that I never agreed with the 2012 United States Preventive Services Task Force to give PSA a “D” rating that has led to decreases in U.S. rates of PSA tes[...]